Immunity to diphtheria and tetanus in England and Wales
Introduction
Immunisation against diphtheria, which commenced on a national scale in the early 1940s, has been a tremendous success, and now, diphtheria is a very rare disease in England and Wales [1], [2]. Unlike diphtheria, tetanus is not an epidemic disease, but is acquired through inoculation of wounds with spores of Clostridium tetani. Neonatal tetanus has been of very low incidence in England and Wales [3] and before 1950 active immunisation with tetanus toxoid was virtually restricted to military personnel. Only in 1964 was universal active immunisation officially sanctioned in England and Wales [4]; although, tetanus vaccination had been performed as part of childhood immunisation schedules before this time [5].
In recent years, in England and Wales there have been a number of alterations and additions to the national vaccination programme [6] which could have a significant impact on the immunity of the population to diphtheria and tetanus. With the aim of improving levels of vaccine uptake, an accelerated schedule of diphtheria, tetanus and pertussis (DTP) immunisation was implemented in the early 1990s [7]. In 1994, a low dose diphtheria component was added to the school leavers dose of tetanus toxoid [8]. Very recently, the traditionally used whole cell component of DTP has been replaced by acellular components [9] and meningococcal C conjugate vaccination has been introduced [10]. The meningococcal C conjugate vaccination programme is targeted at pre-school entry and school leaving and is of particular interest because the vaccines used contain either mutant diphtheria toxin, i.e. CRM197 [11] or tetanus toxoid [12].
The object of this study is to show the immunity profile of the English and Welsh population to diphtheria and tetanus using an appropriately selected set of sera. Such an initiative is timely because it will provide a baseline against which to evaluate the impact of the recently introduced meningococcal C conjugate vaccine immunisation programme, particularly in those aged under 18 years.
Section snippets
Study population and study design
The survey was carried out on residual sera from 18 laboratories which had been used for microbiological or biochemical investigations and then submitted to the Public Health Laboratory Service Seroepidemiology Unit during 1996. The minimum number of sera collected per age group was determined from power calculations using age specific estimates of sero-prevalence of antibody to various vaccine preventable infections including diphtheria [13]. The target number of samples were 100 from yearly
Results
Diphtheria and tetanus antitoxin levels were obtained for 3088 and 3142 sera, respectively. The shortfall from a total of 3300 which should have been tested, according to the study protocol was due to insufficient volumes, inappropriate serum samples (grossly haemolysed, contaminated) and non-specific antibody reactivities.
Fig. 1 shows the distribution of (a) diphtheria antitoxin levels and (b) tetanus antitoxin levels by age group. For diphtheria, we have considered antitoxin levels less than
Discussion
This is the first survey to measure both diphtheria and tetanus antibody levels in a large age and sex stratified set of serum samples collected from England and Wales. The diphtheria antitoxin titres obtained have been classified, according to established criteria [17], levels of less than 0.01 IU/ml indicate susceptibility, levels of 0.01 IU/ml to 0.1 IU/ml provide protection against the toxic manifestations of disease and levels greater than 0.1 IU/ml are fully protective. For the tetanus
Acknowledgments
We would like to thank Dr. Louise Hesketh of the PHLS Sero-epidemiology Unit for the supply of sera, Kelly Batey for technical assistance and Dr. Geoff Barnard of the Regional Endocrine Unit, Southampton General Hospital for the europium labelling of diphtheria toxoid.
References (31)
- et al.
National surveillance of tetanus in England and Wales 1930–79
J. Infect.
(1981) - et al.
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3 and 4 months versus 3, 5 and 9 months of age
Lancet
(1992) - et al.
Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen, time-resolved fluorescence immunoassay
J. Immunol. Methods
(1996) - et al.
Testing for neutralising potential of serum antibodies to tetanus and diphtheria toxin
Lancet
(1992) - et al.
A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera
Biologicals
(1983) - et al.
Diphtheria immunity in UK blood donors
Lancet
(1995) - et al.
Tetanus toxoid for adults
Lancet
(1996) - Ministry of Health. On the state of the public health during six years of war. Report of the Chief Medical Officer of...
Recent trends of diphtheria
Monthly Bulletin of the Ministry of Health and the Public Health Laboratory Service
(1952)Protection against tetanus
Lancet
(1964)
Routine immunisation against infectious diseases
BMJ
Cited by (85)
The immune status against tetanus and diphtheria in healthcare workers in Catalonia
2020, VaccineCitation Excerpt :A study by Ang et al. [13] showed a seroprevalence of tetanus antibodies of 83.2% in males and 62.4% in females, although the study was carried out in people aged 18–79 years and, as the authors pointed out, the prevalence of tetanus immunity decreased with age, especially from age 60–69 years onwards. A 2009 United Kingdom population-based study by Wagner et al. found that 83% of the population was correctly immunized against tetanus [14], well above the 76% identified in a 1996 study [15]. The prevalence of protective antibodies against diphtheria in our study was 68.6%.
Community Protection
2017, Plotkin's VaccinesDiphtheria Toxoid
2017, Plotkin's VaccinesTetanus Toxoid
2017, Plotkin's VaccinesImmunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: An open-label randomised controlled trial
2015, The Lancet Infectious DiseasesCitation Excerpt :Comparisons between groups are expressed as geometric mean ratios, calculated from the back-transformed adjusted or unadjusted log mean difference between groups. The immunogenicity objective of the current study was assessed by between-group comparisons of antigen-specific IgG geometric mean concentrations and the percentage of infants with antigen-specific IgG concentrations equal to or higher than the following accepted thresholds of protection: 0·35 μg/mL for PCV13 serotypes,9 0·15 μg/mL (short-term protection) and 1·0 μg/mL (long-term protection) for anti-polyribosylribitol phosphate IgG,10,11 and 0·1 IU/mL for anti-tetanus toxoid IgG.12,13 For results below the lower limit of quantification for each antigen, values of half the lower limit of quantification were assigned.
Diphtheria vaccination
2014, Vacunas